

Real-World Comparative Effectiveness of Semaglutide 2.4 mg Versus Other Commercially Available Medications for Chronic Weight Management in Adults With Obesity in the United States: A Pragmatic Clinical Study

Results from POSEY (Pragmatic Obesity Semaglutide Trial in EmploYer Setting)

Warren Peters,¹ Tea Monk Fries,² Shilpa Middolu,³ *Lauren Wilson,^{2*}*
Scott H. Lee⁴

¹Loma Linda University, Loma Linda, CA, USA; ²Novo Nordisk, Inc., Plainsboro, NJ, USA; ³Novo Nordisk, Inc., Bengaluru, India;

⁴United Gastroenterologists, Yorba Linda, CA, USA.

*Presenting author.

This trial was sponsored by Novo Nordisk and is registered with ClinicalTrials.gov (NCT05579249).

Medical writing assistance was provided by Anna J. Battershill, MSc, and Michael J. Theisen, PhD, of Peloton Advantage, LLC (an OPEN Health company).

Presenter disclosure


Lauren Wilson reports the following:

- Employee of Novo Nordisk, Inc.

Introduction



In the US, the prevalence of obesity is increasing. In addition to increased health risks and reduced quality of life, employees with obesity are more likely to experience increased absenteeism, premature disability and reduced productivity¹



In the phase 3a STEP 1 study, once-weekly subcutaneous semaglutide 2.4 mg provided clinically relevant weight loss in adults with overweight or obesity,² leading to its FDA approval for weight management in June 2021



This post-approval pragmatic study evaluated the real-world comparative effectiveness of once-weekly subcutaneous semaglutide 2.4 mg versus other commercially available AOMs on body weight reduction in adults with obesity in a multiple-employer US setting

AOM, anti-obesity medication; FDA, US Food and Drug Administration.

1. Yaborough CM, et al. J Occup Environ Med. 2018;60(1):97-107. 2. Wilding JPH, et al. N Engl J Med. 2021;384:989-1002.

Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

Study design

Key inclusion criteria


- Age ≥ 18 years
- BMI: ≥ 30 kg/m²
- Employed at randomisation
- No history of type 1 or type 2 diabetes mellitus



Trial information

Interventional, 1:1 randomised, open-label, parallel-group, active comparator-controlled, 2-armed pragmatic study in a multiple employer setting in the US

- Loma Linda University
- Inland Empire Health Plan



**Intermediate visits occurred according to local clinical practice.
AOM, anti-obesity medication; BMI, body mass index; s.c., subcutaneous.*

Study interventions



Semaglutide 2.4 mg
(Wegovy®)



Other AOMs

Chosen at investigator discretion:

- Orlistat (Xenical®)
- Phentermine/topiramate ER (Qsymia®)
- Naltrexone/bupropion ER (Contrave®)
- Liraglutide 3.0 mg (Saxenda®)



Treatment switching

- Semaglutide group – switching to other AOM was not allowed
- Other AOM group – switching between other AOMs was allowed at investigator discretion

Randomised treatments

- Dispensed by a pharmacy (**drug was not provided**)
- Partial reimbursement (copay assistance) was provided for out-of-pocket costs

AOM, anti-obesity medication.

Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

Study endpoints

Change at Week 52



Primary

- Achieving body weight reduction $\geq 10.0\%$



Confirmatory secondary

- Body weight (%)
- IWQOL-Lite-CT physical function domain score



Select Supportive secondary


- Achieving body weight reduction $\geq 15.0\%$, $\geq 20.0\%$
- Achieving IWQOL-Lite-CT physical function domain score change ≥ 14.6
- Covered by study product $\geq 80\%$ of days



Exploratory

- Treatment satisfaction assessed by TSQM-9 Global Satisfaction total score

Statistical analysis strategies




*Weight management drugs or bariatric surgery.

ITT, intent to treat; MMRM, mixed model for repeated measures.


Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

Participant disposition and treatments



Study impacted by semaglutide shortage

- First participant first visit: January 19, 2023
- Last participant last visit: November 27, 2024



Other AOMs
Observed data – In-Study

Other AOMs	N (%)
Number of participants	242
AOM prescribed at randomisation	
Liraglutide	141 (58.3)
Phentermine/topiramate	96 (39.7)
Naltrexone/bupropion	5 (2.1)
Switched to ≥1 other AOM	65 (26.9)

*Orlistat (Xenical®); phentermine/topiramate ER (Qsymia®); naltrexone/bupropion ER (Contrave®); liraglutide 3.0 mg (Saxenda®).
%, proportion of participants from full analysis set; AOM, anti-obesity medication; FAS, full analysis set; SAS, safety analysis set.

Demographics and baseline characteristics



Female | Male

89.6/10.4%



Mean age

41.3 years



White | Black | Asian | Other*

79.0/10.0/4.8/6.2%



**Mean body
weight**

101.6 kg/ 224.0 lb

Mean BMI

37.4 kg/m²

**Overweight/
OC I/OC II/OC III**

0.6/42.2/33.6/23.6%


**Other refers to American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander and multiple.*

The baseline characteristics at randomisation are reported. The obesity categories are defined as follows: normal weight: 18.5–24.9, overweight: 25.0–29.9, obesity class I: 30.0–34.9, obesity class II: 35.0–39.9, ≥40, obesity class III.


BMI, body mass index; OC, obesity class.

Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

Comorbidities at screening




Number of participants with none to 5 or more comorbidities at screening[†]:




*CVD included the medical history terms coronary heart disease, stable angina pectoris, angina pectoris unstable, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, transient ischemic attack, carotid artery stenosis (≥50% stenosis), peripheral arterial disease (atherosclerotic disease) and peripheral revascularisation or the medical history system organ class of cardiovascular disease within cardiac disorders. [†]Comorbidities evaluated included hypertension, dyslipidaemia, asthma, GERD, CVD, obstructive sleep apnoea, polycystic ovarian syndrome, liver disease, knee osteoarthritis, gout, chronic obstructive pulmonary disease, infertility, kidney disease and psoriasis. %, proportion of participants; CVD, cardiovascular disease; GERD, gastroesophageal reflux disease.

Primary endpoint: Body weight reduction $\geq 10.0\%$

After 52 weeks of treatment



Analysis at week 52	OR	95% CI	P-value
Semaglutide 2.4 mg vs other AOMs	3.18	2.12, 4.78	<0.0001



Analysis at week 52	OR	95% CI	P-value
Semaglutide 2.4 mg vs other AOMs	9.20	6.11, 13.83	<0.0001


**All observations while adherent to treatment and not initiating other anti-obesity therapies.
AOM, anti-obesity medication; CI, confidence interval; OR, odds ratio.*

Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

Secondary endpoint: Change in body weight (%)


Observed and estimated means – Treatment Policy Strategy after 52 weeks of treatment

Observed Mean % Change
Mean baseline body weight: 101.6 kg



Semaglutide 2.4 mg =	250	218	218	212		211		207
Other AOMs =	250	225	209	200		186		177

Treatment Policy Strategy
Mean baseline body weight: 101.6 kg




Numbers shown in the lower panel of the figure (left) are numbers of participants contributing to the mean.
AOM, anti-obesity medication; CI, confidence interval; ETD, estimated treatment difference; SEM, standard error of the mean.

Secondary endpoint: Change in body weight (%)


Observed and estimated means – Hypothetical Strategy after 52 weeks of treatment

Observed Mean % Change
Mean baseline body weight: 101.6 kg



Semaglutide 2.4 mg =	250	212	213	202	191	111
Other AOMs =	250	220	207	189	148	66



Hypothetical Strategy
Mean baseline body weight: 101.6 kg



Numbers shown in the lower panel of the figure (left) are numbers of participants contributing to the mean.
AOM, anti-obesity medication; CI, confidence interval; ETD, estimated treatment difference; SEM, standard error of the mean.


Supportive secondary endpoints – Categorical weight loss

Observed proportions after 52 weeks of treatment



Supportive secondary endpoints – Categorical weight loss

Estimated odds ratio after 52 weeks of treatment




Observed data.
AOM, anti-obesity medication; CI, confidence interval; OR, odds ratio.

Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

IWQOL-Lite-CT

Impact of Weight on Quality of Life-Lite for Clinical Trials Version^{1,2}



Scoring²:

- 1 = never; not true at all
- 2 = rarely; a little true
- 3 = sometimes; moderately true
- 4 = usually; mostly true
- 5 = always; completely true
- Larger values reflect *worse* outcomes


Composite scores range from 0 to 100, with higher scores reflecting *better* outcomes

Secondary endpoint: Change in IWQOL-Lite-CT physical function score

Observed and estimated means – Treatment Policy Strategy after 52 weeks of treatment

Observed Mean Change


Mean baseline IWQOL-Lite-CT physical function score: 45.2



Semaglutide 2.4 mg =	250	207	189
Other AOMs =	250	185	163

Treatment Policy Strategy

Mean baseline IWQOL-Lite-CT physical function score: 45.2




**Estimated means. Error bars are ± standard error of the mean. Numbers shown in the lower panel of the figure (left) are numbers of participants contributing to the mean.
AOM, anti-obesity medication; CI, confidence interval; ETD, estimated treatment difference; IWQOL-Lite-CT, Impact of Weight on Quality of Life – Lite for Clinical Trials; SEM, standard error of the mean.*

Secondary endpoint: Change in IWQOL-Lite-CT physical function score

Observed and estimated means – Hypothetical Strategy after 52 weeks of treatment

Observed Mean Change


Mean baseline IWQOL-Lite-CT physical function score: 45.2



Semaglutide 2.4 mg = 250 188 110
Other AOMs = 250 146 63

Hypothetical Strategy


Mean baseline IWQOL-Lite-CT physical function score: 45.2



*Estimated means. Error bars are $\pm$ standard error of the mean. Numbers shown in the lower panel of the figure (left) are numbers of participants contributing to the mean.
AOM, anti-obesity medication; CI, confidence interval; ETD, estimated treatment difference; IWQOL-Lite-CT, Impact of Weight on Quality of Life – Lite for Clinical Trials; SEM, standard error of the mean.

Secondary endpoint: Change in IWQOL-Lite-CT physical function score ≥ 14.6

Observed proportions – Treatment Policy Strategy after 52 weeks of treatment




Statistical Analysis at Week 52 – Treatment Policy Strategy

Analysis at week 52	OR	95% CI	P-value
Semaglutide 2.4 mg vs other AOMs	1.47	0.91, 2.38	0.1163

AOM, anti-obesity medication; CI, confidence interval; IWQOL-Lite-CT, Impact of Weight on Quality of Life – Lite for Clinical Trials; OR, odds ratio.

Secondary endpoint: Covered by study product $\geq 80\%$ of days

Observed proportions – Treatment Policy Strategy after 52 weeks of treatment



Exploratory endpoint: TSQM-9 Global Satisfaction total score


Observed proportions – Treatment Policy Strategy after 52 weeks of treatment

Treatment	N	Mean (SD)	Min, max
In-Study			
Semaglutide 2.4 mg	188	80.1 (24.4)	0, 100
Other AOMs	161	67.3 (30.6)	0, 100
Adherent			
Semaglutide 2.4 mg	110	87.7 (16.5)	14.3, 100
Other AOMs	62	77.6 (22.2)	28.6, 100

The TSQM-9 is a modified self-administered questionnaire that does not consider the role of side effects in satisfaction; scores range from 0 to 100, with higher scores indicating better treatment satisfaction. There are 3 key domains; effectiveness, convenience and global satisfaction.¹
AOM, anti-obesity medication; N, number of participants with an observation at the visit; SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire for Medication.
¹. Bharmal M, et al. Health Qual Life Outcomes. 2009;7:36.

Safety

Observed proportions



AE, adverse event; AOM, anti-obesity medication; SAE, serious adverse event.

Peters W, et al. Presented at ISPOR 2026, May 17-20, 2026; Philadelphia, PA, USA.

POSEY, STEP 1 and STEP 8: Efficacy results

Indirect treatment comparison: Hypothetical Strategy*

	POSEY		STEP 1		STEP 8		
Investigational agent/comparator	Semaglutide 2.4 mg	Other AOMs	Semaglutide 2.4 mg	Placebo	Semaglutide 2.4 mg	Liraglutide 3.0 mg	Placebo
Change in BW (%)	−15.45	−7.74	−16.86	−2.44	−17.06	−6.59	−1.79
Participants achieving 10% weight loss (%)	79.3	51.5	74.8	11.8	73.6	28.3	15.9
Participants achieving 15% weight loss (%)	59.5	21.2	54.8	5	56.6	14.1	5.8
Participants achieving 20% weight loss (%)	30.6	9.1	34.8	2	40.6	6.5	2.9

**In STEP studies, Hypothetical Strategy refers to the hypothetical estimand and on-treatment data; in POSEY, Hypothetical Strategy refers to the additional estimand and adherent data.
AOM, anti-obesity medication; BW, body weight.*

Conclusions



Semaglutide 2.4 mg was superior to other AOMs with respect to participants achieving $\geq 10.0\%$ body weight reduction and change in body weight (%)



More participants treated with semaglutide 2.4 mg achieved $\geq 15\%$ and $\geq 20\%$ body weight reduction from baseline compared with other AOMs



A trend towards greater improvement in IWQOL-Lite-CT physical function score was observed with semaglutide 2.4 mg compared with other AOMs, though this difference did not reach statistical significance



Safety and tolerability were consistent with the overall well-established profile of semaglutide



These findings demonstrate real-world effectiveness of semaglutide 2.4 mg comparable to that observed in the phase 3a STEP trials

Acknowledgments

- We gratefully acknowledge and thank the participants and all personnel involved in the study
- The study was funded by Novo Nordisk A/S